Loading…

Synthesis and evaluation of nitro 5-deazaflavin-pyrrolecarboxamide(s) hybrid molecules as novel DNA targeted bioreductive antitumor agents

A series of 6-nitro-5-deazaflavins bearing at N(3) or N(10) position the pyrrolecarboxamide(s) group as DNA minor groove binder has been synthesized. These hybrid molecules show similar redox properties to those of 6-nitro-5-deazaflavins with no pyrrolecarboxamide(s) group, suggesting that they gene...

Full description

Saved in:
Bibliographic Details
Published in:Bioorganic & medicinal chemistry 1998-03, Vol.6 (3), p.301-314
Main Authors: Kanaoka, Yoshitomo, Ikeuchi, Yoshihiro, Kawamoto, Tetsuji, Bessho, Kiyoshi, Akimoto, Naoshige, Mikata, Yuji, Nishida, Mamiko, Yano, Shigenobu, Sasaki, Takuma, Yoneda, Fumio
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c2074-a6363c4c7976cef49ab2ed62dbd5e2177b93e393757c2e6ad6ab9713a64302253
cites cdi_FETCH-LOGICAL-c2074-a6363c4c7976cef49ab2ed62dbd5e2177b93e393757c2e6ad6ab9713a64302253
container_end_page 314
container_issue 3
container_start_page 301
container_title Bioorganic & medicinal chemistry
container_volume 6
creator Kanaoka, Yoshitomo
Ikeuchi, Yoshihiro
Kawamoto, Tetsuji
Bessho, Kiyoshi
Akimoto, Naoshige
Mikata, Yuji
Nishida, Mamiko
Yano, Shigenobu
Sasaki, Takuma
Yoneda, Fumio
description A series of 6-nitro-5-deazaflavins bearing at N(3) or N(10) position the pyrrolecarboxamide(s) group as DNA minor groove binder has been synthesized. These hybrid molecules show similar redox properties to those of 6-nitro-5-deazaflavins with no pyrrolecarboxamide(s) group, suggesting that they generate stable one- and two-electron reduction product(s). Electrolytic reductions of the hybrid molecules were carried out at a controlled potential under anaerobic conditions in the presence of plasmid pBR322 DNA. Significant conversions of the supercoiled circular pBR322 DNA (form I) to the open circular DNA (form II) have been found by treatment with the reductively activated 6-nitro-5-deazaflavin derivatives. Their DNA damaging effects have been found to be enhanced as the number of pyrrolecarboxamide group as the DNA binder increases. Antitumor activities of the hybrid molecules towards KB and L1210 cells were evaluated in vitro. It has been found that the antitumor effects of the compounds on KB cells slightly change and those on L1210 cells decrease as the number of the pyrrolecarboxamide group increases. These results reveal that the combination of 6-nitro-5-deazaflavin molecule with the pyrrolecarboxamide(s) group increase the DNA binding properties of the compounds, giving rise to promoted DNA damaging effects, and also suggest that the combination would affect the capacity of the compounds to act as the substrate for intracellular reductases and/or the cellular uptake of the compounds.
doi_str_mv 10.1016/S0968-0896(97)10036-0
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79826618</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0968089697100360</els_id><sourcerecordid>79826618</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2074-a6363c4c7976cef49ab2ed62dbd5e2177b93e393757c2e6ad6ab9713a64302253</originalsourceid><addsrcrecordid>eNqFUctu1DAUtRCoTAufUMkr1C4CfiR2vEJVoYBUwaKwtm7sm9YoiQfbiRg-ga8m0xl1y-ouzkv3HELOOXvLGVfv7phRbcVaoy6MvuSMSVWxZ2TDa1VXUhr-nGyeKC_Jac4_GWOiNvyEnJhGtaKtN-Tv3W4qD5hDpjB5igsMM5QQJxp7OoWSIm0qj_AH-gGWMFXbXUpxQAepi79hDB4v8iV92HUpeDrukXnA1SzTKS440A9fr2iBdI8FPe1CTOhnV8KCa14JZR5jonCPU8mvyIsehoyvj_eM_Lj5-P36c3X77dOX66vbygmm6wqUVNLVThutHPa1gU6gV8J3vkHBte6MRGmkbrQTqMAr6IzmElQtmRCNPCNvDr7bFH_NmIsdQ3Y4DDBhnLPVphVK8XYlNgeiSzHnhL3dpjBC2lnO7H4D-7iB3RdsjbaPG1i26s6PAXM3on9SHUtf8fcHHNcvl4DJZhdwcuhDQlesj-E_Cf8Aoi6ZUA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79826618</pqid></control><display><type>article</type><title>Synthesis and evaluation of nitro 5-deazaflavin-pyrrolecarboxamide(s) hybrid molecules as novel DNA targeted bioreductive antitumor agents</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Kanaoka, Yoshitomo ; Ikeuchi, Yoshihiro ; Kawamoto, Tetsuji ; Bessho, Kiyoshi ; Akimoto, Naoshige ; Mikata, Yuji ; Nishida, Mamiko ; Yano, Shigenobu ; Sasaki, Takuma ; Yoneda, Fumio</creator><creatorcontrib>Kanaoka, Yoshitomo ; Ikeuchi, Yoshihiro ; Kawamoto, Tetsuji ; Bessho, Kiyoshi ; Akimoto, Naoshige ; Mikata, Yuji ; Nishida, Mamiko ; Yano, Shigenobu ; Sasaki, Takuma ; Yoneda, Fumio</creatorcontrib><description>A series of 6-nitro-5-deazaflavins bearing at N(3) or N(10) position the pyrrolecarboxamide(s) group as DNA minor groove binder has been synthesized. These hybrid molecules show similar redox properties to those of 6-nitro-5-deazaflavins with no pyrrolecarboxamide(s) group, suggesting that they generate stable one- and two-electron reduction product(s). Electrolytic reductions of the hybrid molecules were carried out at a controlled potential under anaerobic conditions in the presence of plasmid pBR322 DNA. Significant conversions of the supercoiled circular pBR322 DNA (form I) to the open circular DNA (form II) have been found by treatment with the reductively activated 6-nitro-5-deazaflavin derivatives. Their DNA damaging effects have been found to be enhanced as the number of pyrrolecarboxamide group as the DNA binder increases. Antitumor activities of the hybrid molecules towards KB and L1210 cells were evaluated in vitro. It has been found that the antitumor effects of the compounds on KB cells slightly change and those on L1210 cells decrease as the number of the pyrrolecarboxamide group increases. These results reveal that the combination of 6-nitro-5-deazaflavin molecule with the pyrrolecarboxamide(s) group increase the DNA binding properties of the compounds, giving rise to promoted DNA damaging effects, and also suggest that the combination would affect the capacity of the compounds to act as the substrate for intracellular reductases and/or the cellular uptake of the compounds.</description><identifier>ISSN: 0968-0896</identifier><identifier>EISSN: 1464-3391</identifier><identifier>DOI: 10.1016/S0968-0896(97)10036-0</identifier><identifier>PMID: 9568284</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Animals ; Antineoplastic Agents - chemical synthesis ; Antineoplastic Agents - pharmacology ; DNA - drug effects ; DNA - metabolism ; DNA Damage ; Drug Screening Assays, Antitumor ; Flavins - chemical synthesis ; Flavins - pharmacology ; Humans ; KB Cells ; Leukemia L1210 - drug therapy ; Mice ; Oxidation-Reduction ; Pyrroles - chemical synthesis ; Pyrroles - pharmacology ; Structure-Activity Relationship</subject><ispartof>Bioorganic &amp; medicinal chemistry, 1998-03, Vol.6 (3), p.301-314</ispartof><rights>1997 Elsevier Science Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2074-a6363c4c7976cef49ab2ed62dbd5e2177b93e393757c2e6ad6ab9713a64302253</citedby><cites>FETCH-LOGICAL-c2074-a6363c4c7976cef49ab2ed62dbd5e2177b93e393757c2e6ad6ab9713a64302253</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9568284$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kanaoka, Yoshitomo</creatorcontrib><creatorcontrib>Ikeuchi, Yoshihiro</creatorcontrib><creatorcontrib>Kawamoto, Tetsuji</creatorcontrib><creatorcontrib>Bessho, Kiyoshi</creatorcontrib><creatorcontrib>Akimoto, Naoshige</creatorcontrib><creatorcontrib>Mikata, Yuji</creatorcontrib><creatorcontrib>Nishida, Mamiko</creatorcontrib><creatorcontrib>Yano, Shigenobu</creatorcontrib><creatorcontrib>Sasaki, Takuma</creatorcontrib><creatorcontrib>Yoneda, Fumio</creatorcontrib><title>Synthesis and evaluation of nitro 5-deazaflavin-pyrrolecarboxamide(s) hybrid molecules as novel DNA targeted bioreductive antitumor agents</title><title>Bioorganic &amp; medicinal chemistry</title><addtitle>Bioorg Med Chem</addtitle><description>A series of 6-nitro-5-deazaflavins bearing at N(3) or N(10) position the pyrrolecarboxamide(s) group as DNA minor groove binder has been synthesized. These hybrid molecules show similar redox properties to those of 6-nitro-5-deazaflavins with no pyrrolecarboxamide(s) group, suggesting that they generate stable one- and two-electron reduction product(s). Electrolytic reductions of the hybrid molecules were carried out at a controlled potential under anaerobic conditions in the presence of plasmid pBR322 DNA. Significant conversions of the supercoiled circular pBR322 DNA (form I) to the open circular DNA (form II) have been found by treatment with the reductively activated 6-nitro-5-deazaflavin derivatives. Their DNA damaging effects have been found to be enhanced as the number of pyrrolecarboxamide group as the DNA binder increases. Antitumor activities of the hybrid molecules towards KB and L1210 cells were evaluated in vitro. It has been found that the antitumor effects of the compounds on KB cells slightly change and those on L1210 cells decrease as the number of the pyrrolecarboxamide group increases. These results reveal that the combination of 6-nitro-5-deazaflavin molecule with the pyrrolecarboxamide(s) group increase the DNA binding properties of the compounds, giving rise to promoted DNA damaging effects, and also suggest that the combination would affect the capacity of the compounds to act as the substrate for intracellular reductases and/or the cellular uptake of the compounds.</description><subject>Animals</subject><subject>Antineoplastic Agents - chemical synthesis</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>DNA - drug effects</subject><subject>DNA - metabolism</subject><subject>DNA Damage</subject><subject>Drug Screening Assays, Antitumor</subject><subject>Flavins - chemical synthesis</subject><subject>Flavins - pharmacology</subject><subject>Humans</subject><subject>KB Cells</subject><subject>Leukemia L1210 - drug therapy</subject><subject>Mice</subject><subject>Oxidation-Reduction</subject><subject>Pyrroles - chemical synthesis</subject><subject>Pyrroles - pharmacology</subject><subject>Structure-Activity Relationship</subject><issn>0968-0896</issn><issn>1464-3391</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><recordid>eNqFUctu1DAUtRCoTAufUMkr1C4CfiR2vEJVoYBUwaKwtm7sm9YoiQfbiRg-ga8m0xl1y-ouzkv3HELOOXvLGVfv7phRbcVaoy6MvuSMSVWxZ2TDa1VXUhr-nGyeKC_Jac4_GWOiNvyEnJhGtaKtN-Tv3W4qD5hDpjB5igsMM5QQJxp7OoWSIm0qj_AH-gGWMFXbXUpxQAepi79hDB4v8iV92HUpeDrukXnA1SzTKS440A9fr2iBdI8FPe1CTOhnV8KCa14JZR5jonCPU8mvyIsehoyvj_eM_Lj5-P36c3X77dOX66vbygmm6wqUVNLVThutHPa1gU6gV8J3vkHBte6MRGmkbrQTqMAr6IzmElQtmRCNPCNvDr7bFH_NmIsdQ3Y4DDBhnLPVphVK8XYlNgeiSzHnhL3dpjBC2lnO7H4D-7iB3RdsjbaPG1i26s6PAXM3on9SHUtf8fcHHNcvl4DJZhdwcuhDQlesj-E_Cf8Aoi6ZUA</recordid><startdate>199803</startdate><enddate>199803</enddate><creator>Kanaoka, Yoshitomo</creator><creator>Ikeuchi, Yoshihiro</creator><creator>Kawamoto, Tetsuji</creator><creator>Bessho, Kiyoshi</creator><creator>Akimoto, Naoshige</creator><creator>Mikata, Yuji</creator><creator>Nishida, Mamiko</creator><creator>Yano, Shigenobu</creator><creator>Sasaki, Takuma</creator><creator>Yoneda, Fumio</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199803</creationdate><title>Synthesis and evaluation of nitro 5-deazaflavin-pyrrolecarboxamide(s) hybrid molecules as novel DNA targeted bioreductive antitumor agents</title><author>Kanaoka, Yoshitomo ; Ikeuchi, Yoshihiro ; Kawamoto, Tetsuji ; Bessho, Kiyoshi ; Akimoto, Naoshige ; Mikata, Yuji ; Nishida, Mamiko ; Yano, Shigenobu ; Sasaki, Takuma ; Yoneda, Fumio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2074-a6363c4c7976cef49ab2ed62dbd5e2177b93e393757c2e6ad6ab9713a64302253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - chemical synthesis</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>DNA - drug effects</topic><topic>DNA - metabolism</topic><topic>DNA Damage</topic><topic>Drug Screening Assays, Antitumor</topic><topic>Flavins - chemical synthesis</topic><topic>Flavins - pharmacology</topic><topic>Humans</topic><topic>KB Cells</topic><topic>Leukemia L1210 - drug therapy</topic><topic>Mice</topic><topic>Oxidation-Reduction</topic><topic>Pyrroles - chemical synthesis</topic><topic>Pyrroles - pharmacology</topic><topic>Structure-Activity Relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kanaoka, Yoshitomo</creatorcontrib><creatorcontrib>Ikeuchi, Yoshihiro</creatorcontrib><creatorcontrib>Kawamoto, Tetsuji</creatorcontrib><creatorcontrib>Bessho, Kiyoshi</creatorcontrib><creatorcontrib>Akimoto, Naoshige</creatorcontrib><creatorcontrib>Mikata, Yuji</creatorcontrib><creatorcontrib>Nishida, Mamiko</creatorcontrib><creatorcontrib>Yano, Shigenobu</creatorcontrib><creatorcontrib>Sasaki, Takuma</creatorcontrib><creatorcontrib>Yoneda, Fumio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Bioorganic &amp; medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kanaoka, Yoshitomo</au><au>Ikeuchi, Yoshihiro</au><au>Kawamoto, Tetsuji</au><au>Bessho, Kiyoshi</au><au>Akimoto, Naoshige</au><au>Mikata, Yuji</au><au>Nishida, Mamiko</au><au>Yano, Shigenobu</au><au>Sasaki, Takuma</au><au>Yoneda, Fumio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Synthesis and evaluation of nitro 5-deazaflavin-pyrrolecarboxamide(s) hybrid molecules as novel DNA targeted bioreductive antitumor agents</atitle><jtitle>Bioorganic &amp; medicinal chemistry</jtitle><addtitle>Bioorg Med Chem</addtitle><date>1998-03</date><risdate>1998</risdate><volume>6</volume><issue>3</issue><spage>301</spage><epage>314</epage><pages>301-314</pages><issn>0968-0896</issn><eissn>1464-3391</eissn><abstract>A series of 6-nitro-5-deazaflavins bearing at N(3) or N(10) position the pyrrolecarboxamide(s) group as DNA minor groove binder has been synthesized. These hybrid molecules show similar redox properties to those of 6-nitro-5-deazaflavins with no pyrrolecarboxamide(s) group, suggesting that they generate stable one- and two-electron reduction product(s). Electrolytic reductions of the hybrid molecules were carried out at a controlled potential under anaerobic conditions in the presence of plasmid pBR322 DNA. Significant conversions of the supercoiled circular pBR322 DNA (form I) to the open circular DNA (form II) have been found by treatment with the reductively activated 6-nitro-5-deazaflavin derivatives. Their DNA damaging effects have been found to be enhanced as the number of pyrrolecarboxamide group as the DNA binder increases. Antitumor activities of the hybrid molecules towards KB and L1210 cells were evaluated in vitro. It has been found that the antitumor effects of the compounds on KB cells slightly change and those on L1210 cells decrease as the number of the pyrrolecarboxamide group increases. These results reveal that the combination of 6-nitro-5-deazaflavin molecule with the pyrrolecarboxamide(s) group increase the DNA binding properties of the compounds, giving rise to promoted DNA damaging effects, and also suggest that the combination would affect the capacity of the compounds to act as the substrate for intracellular reductases and/or the cellular uptake of the compounds.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>9568284</pmid><doi>10.1016/S0968-0896(97)10036-0</doi><tpages>14</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0968-0896
ispartof Bioorganic & medicinal chemistry, 1998-03, Vol.6 (3), p.301-314
issn 0968-0896
1464-3391
language eng
recordid cdi_proquest_miscellaneous_79826618
source ScienceDirect Freedom Collection 2022-2024
subjects Animals
Antineoplastic Agents - chemical synthesis
Antineoplastic Agents - pharmacology
DNA - drug effects
DNA - metabolism
DNA Damage
Drug Screening Assays, Antitumor
Flavins - chemical synthesis
Flavins - pharmacology
Humans
KB Cells
Leukemia L1210 - drug therapy
Mice
Oxidation-Reduction
Pyrroles - chemical synthesis
Pyrroles - pharmacology
Structure-Activity Relationship
title Synthesis and evaluation of nitro 5-deazaflavin-pyrrolecarboxamide(s) hybrid molecules as novel DNA targeted bioreductive antitumor agents
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T16%3A21%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Synthesis%20and%20evaluation%20of%20nitro%205-deazaflavin-pyrrolecarboxamide(s)%20hybrid%20molecules%20as%20novel%20DNA%20targeted%20bioreductive%20antitumor%20agents&rft.jtitle=Bioorganic%20&%20medicinal%20chemistry&rft.au=Kanaoka,%20Yoshitomo&rft.date=1998-03&rft.volume=6&rft.issue=3&rft.spage=301&rft.epage=314&rft.pages=301-314&rft.issn=0968-0896&rft.eissn=1464-3391&rft_id=info:doi/10.1016/S0968-0896(97)10036-0&rft_dat=%3Cproquest_cross%3E79826618%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2074-a6363c4c7976cef49ab2ed62dbd5e2177b93e393757c2e6ad6ab9713a64302253%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=79826618&rft_id=info:pmid/9568284&rfr_iscdi=true